|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/70 | |
| A61K 31/4535 | |||
| A61K 31/5517 | |||
| A61K 9/00 | |||
| A61P 25/20 |
| (11) | Patento numeris | 2604257 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13158781.8 |
| Europos patento paraiškos padavimo data | 2008-08-07 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-06-19 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-06-28 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 954501 P | 2007-08-07 | US |
| (72) |
Palmer, Pamela, US
Tzannis, Stelios, US
Schreck, Thomas, US
|
| (73) |
Acelrx Pharmaceuticals, Inc.,
575 Chesapeake Drive, Redwood City, CA 94063,
US
|
| (54) | Oral transmucosal dosage forms comprising sufentanil and triazolam |
| Oral transmucosal dosage forms comprising sufentanil and triazolam |